AMP-activated protein kinase (AMPK) is viewed as a fuel sensor for glucose and lipid metabolism. To understand better the physiological role of the catalytic AMPK subunit isoforms, we generated two knockout mouse models with the α1 (AMPKα1 −/− ) and α2 (AMPKα2 −/− ) catalytic subunit genes deleted. No defect in glucose homoeostasis was observed in AMPKα1 −/− mice. On the other hand, AMPKα2 −/− mice presented high plasma glucose levels and low plasma insulin concentrations in the fed period and during the glucose tolerance test. Nevertheless, in isolated AMPKα2 −/− pancreatic islets, glucose-stimulated insulin secretion was not affected. Surprisingly, AMPKα2 −/− mice were insulin-resistant and had reduced muscle glycogen synthesis as assessed in vivo by the hyperinsulinaemic euglycaemic clamp procedure. Reduction of insulin sensitivity and glycogen synthesis were not dependent on the lack of AMPK in skeletal muscle, since mice expressing a dominant inhibitory mutant of AMPK in skeletal muscle were not affected and since insulinstimulated glucose transport in incubated muscles in vitro was normal in AMPKα2 −/− muscles. Furthermore, AMPKα2 −/− mice have a higher sympathetic tone, as shown by increased catecholamine urinary excretion.
Introduction
In mammals, the control of glucose homoeostasis is governed by the balance between glucose absorption from the intestine, endogenous production by the liver and uptake and metabolism by peripheral tissues. This requires continuous adaptation of metabolic pathways to maintain glycaemia in the physiological range. The AMP-activated protein kinase (AMPK) has been proposed to act as a 'metabolic master switch' capable of mediating the cellular adaptation to nutritional environmental variations [1] . AMPK is a ubiquitous serine/threonine protein kinase activated in response to environmental or nutritional stress factors which deplete intracellular ATP levels, including heat shock, hypoxia, hypoglycaemia and prolonged exercise [2] . Regardless, the result of AMPK activation is the inhibition of energyconsuming biosynthetic pathways, such as fatty acid and sterol synthesis, and activation of ATP-producing catabolic pathways, such as fatty acid oxidation. Regulation of AMPK activity is complex , involving an allosteric activation by AMP in response to a rise in intracellular AMP/ATP ratio and a covalent modification by phosphorylation via an upstream AMPK kinase also allosterically activated by AMP [3] . Recently, several studies have demonstrated that AMPK can Key words: glucose metabolism, insulin resistance.
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be activated by other mechanisms that do not appear to involve changes in adenine nucleotides [4, 5] . AMPK is a heterotrimeric complex consisting of a catalytic subunit (α) and two regulatory subunits (β and γ ). Two isoforms have been identified for both the α (α1 and α2) and β (β1 and β2) subunits and three isoforms have been reported for the γ subunit (γ 1, γ 2 and γ 3), all of which are encoded by different genes [1] .
Important progress has recently been made in the understanding of the physiological role of AMPK. In the present review we will focus on the regulation of glucose and lipid metabolism by AMPK. Metabolic exploration of knockout mouse models for the AMPK catalytic subunit genes has made it possible to study distinct physiological functions for both isoforms. Particularly, these studies have highlighted the involvement of the AMPKα2 subunit in the regulation of glucose homoeostasis through the autonomous nervous system.
Metabolic action of AMPK
When AMPK is activated by 5-amino-4-imidazolecarboxamide riboside (AICAR), in vitro [6] [7] [8] or in vivo [9, 10] muscle glucose uptake [6, 8] and fatty acid oxidation [7] increase. It was also demonstrated that leptin enhances fatty acid oxidation in skeletal muscle through a reduction of acetyl-CoA carboxylase (ACC) activity by activation of the AMPK, both by direct action and through activation via the sympathetic nervous system [5] . In vitro, incubation of rat hepatocytes with AICAR has been shown to decrease hepatic gluconeogenesis by inhibiting fructose-1,6-biphosphatase activity [11] . A decrease in endogenous hepatic production after activation of AMPK has also been demonstrated in vivo after metformin administration [4] or during AICAR infusion during an isoglycaemic clamp study [9] . AMPK also plays an important role in the regulation of fat metabolism. Indeed, lipolysis is inhibited by AICARinduced AMPK activation in lean and obese rodents, in vivo [9, 10] and in vitro [12, 13] , suggesting that hormone-sensitive lipase (HSL) is a target of AMPK in adipocytes. Furthermore, a decrease in triglyceride (triacylglycerol) levels can be observed during AICAR infusion in both lean and obese rodents [9] , suggesting that activation of AMPK decreases lipogenesis in liver. This result is in agreement with AICAR-induced inhibition of mitochondrial glycerol-3-phosphate acyltransferase activity in vitro [14] . So, by promoting insulin-independent glucose uptake, enhancing lipid oxidation in skeletal muscle and reducing triglyceride synthesis and adipocyte lipolysis, activation of AMPK has pleiotropic beneficial effects on metabolic homoeostasis. For these different reasons, AMPK has emerged as a potential therapeutic molecular target for the treatment of Type 2 diabetes and obesity [2] .
Distinct physiological roles for α1 and α2 catalytic subunits of AMPK
An important question is to what extent the α1 and α2 catalytic subunits could have specific targets. The α2 isoform has been proposed to play a major role in controlling metabolism, at least in skeletal muscle, but activation of the α1 isoform is also observed during some interventions in skeletal muscle [5, 8, 15, 16] . In contrast, analysis of specific catalytic isoforms action in other tissue has not been extensively studied. Indeed, most of the actions of AMPK have been described after pharmacological activation of AMPK by AICAR. Because tissue effects observed upon AICAR administration may be the result of the activation of both α1 and α2 catalytic isoforms, it is impossible to distinguish the specific actions of each isoform. To get more insight into this issue, we have created mice invalidated for both genes. Mice lacking the α1 isoform present no defect in glucose homoeostasis, as assessed by the glucose tolerance test (B. Viollet and F. Andreelli, unpublished work). In contrast, mice lacking the α2 isoform clearly exhibited glucose intolerance and reduced insulin sensitivity [16a] . Thus, our data are consistent with a more predominant role for the α2 catalytic subunit in controlling glucose homoeostasis than the α1 isoform.
Metabolic characteristics of AMPKα2
−/− mice Because AMPKα1 −/− mice have no apparent metabolic defect, we focused on the metabolic exploration of AMPKα2 −/− mice. AMPKα2 −/− mice presented high plasma glucose levels and low plasma insulin levels in the fed period and during glucose challenge. The mechanism behind the impairment of glucose-induced insulin-secretion capacity in AMPKα2 −/− mice is not clear. Few data are available concerning regulation of insulin release by AMPK. Previous reports show that enhancement of insulin secretion by increasing glucose concentration is associated with a decrease in AMPK activity in isolated INS-1 cells [17] and in MIN6 cells [18] . Furthermore, AICAR inhibits glucose-mediated insulin secretion in INS-1 cells [16] . In contrast, AICAR stimulated insulin secretion at low glucose levels but inhibited insulin release at saturating glucose concentrations in rat isolated pancreatic islets [16] . Interestingly, we observed that while glucose-induced insulin secretion is impaired in AMPKα2 −/− mice, isolated pancreatic islets from AMPKα2 −/− mice were able to secrete insulin in response to increased glucose concentrations in vitro as well as isolated islets from wild-type mice. This signifies that extra-pancreatic factors probably play a role in the reduction of glucose-induced insulin secretion in vivo in AMPKα2 −/− mice. Likewise, chronic exposure of the β cells to elevated levels of free (non-esterified) fatty acids have been shown to impair β cell function and insulin secretion in vivo [19] . This could be the case in the AMPKα2 −/− mice since free fatty acids levels are chronically elevated in these mice.
AMPK has been also involved in the regulation of lipid metabolism in rodents [1, 2] . AMPK exerts an antilipolytic effect both in vitro and in vivo. In accordance with these studies, we showed that AMPKα2 −/− mice exhibit significantly higher free fatty acids levels than controls in both the fasted and the fed states, probably by chronically enhanced lipolysis. This suggested that the α2 subunit inhibits HSL activity in adipocytes. However, we cannot exclude that lipolysis is enhanced in AMPKα2 −/− mice because their insulin levels were chronically low or because sympathetic nervous activity was increased. Activation of AMPK also decreases hepatic steatosis. This is confirmed by a decrease in triglyceride levels in lean and obese rodents during AICAR infusion [9] . One could expect that inactivation of AMPK leads to increased triglyceride levels and enhanced hepatic lipogenesis. This is not the case in AMPKα2 −/− mice, who exhibit triglyceride levels and hepatic lipid contents similar to those in control mice. This suggested that the remaining α1 subunit activity in AMPKα2 −/− mice is sufficient to control hepatic lipogenesis and that the key enzymes of lipogenesis are equal targets of both catalytic isoforms of the kinase.
AMPKα2 controls whole-body insulin sensitivity
To our surprise, AMPKα2 −/− mice exhibit decreased insulin sensitivity in muscle, as assessed by a hyperinsulinaemic euglycaemic clamp procedure. Indeed, the AMPK system has been considered to be independent of the insulin pathway and one could expect that a lack of AMPK activity cannot modify insulin sensitivity. During the clamp study, the infused glucose is driven preferentially into skeletal muscle and only the insulin-dependent fraction of glucose uptake was explored. We showed that insulin resistance in AMPKα2 −/− mice was associated with a dramatic reduction in glycogen synthesis in skeletal muscle confirmed both by incorporation of 3 H in glycogen and evaluation of total glycogen content in skeletal muscle. Interestingly, insulin sensitivity of muscle glucose transport in incubated muscles in vitro was similar in control and AMPKα2 −/− mice. In addition, we showed that transgenic mice overexpressing a dominant-inhibitory mutant of AMPK in skeletal muscle [20] did not present a reduction in insulin sensitivity or a defect in muscle glycogen synthesis. These data strongly suggested that partial or total inactivation of AMPK in skeletal muscle is unable by itself to induce insulin resistance or impaired glycogen synthesis.
Role of AMPKα2 in co-ordinating autonomous nervous system activity
The observation that AMPKα2 −/− mice exhibit metabolic defects in vivo but not in isolated organs raised the question of whether AMPKα2 controls glucose metabolism through modification of peripheral or central nervous system activity. The α2 subunit of AMPK is highly expressed in neurons and activated astrocytes [21] , suggesting that lack of neuronal AMPKα2 activity could interfere with sympathetic effects on energy metabolism. Indeed, we showed that AMPKα2 −/− mice exhibit a significant increase in 24 h urinary excretion, indicating chronic sympathetic activation [22] . Furthermore, catecholamine overproduction is known to inhibit insulin secretion, reduce insulin-stimulated glucose uptake in skeletal muscles and alter muscle glycogen synthesis, all of these defects being present in AMPKα2
−/− mice in vivo.
In conclusion, we demonstrated that whole-body deletion of the AMPKα2 isoform is associated with glucose intolerance, lower insulin secretion, insulin resistance and a defect in glycogen synthesis in skeletal muscle. These defects are related to increased catecholamine excretion, suggesting altered function of the autonomic nervous system in integrating peripheral metabolic signals (Figure 1) . Finally, analysis of AMPKα2 −/− mice illustrates the complexity in identifying the precise role of the AMPK signalling pathway in the regulation of metabolic processes.
